Semax

What it is

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) representing a fragment of adrenocorticotropic hormone (ACTH 4-7) with a tripeptide extension that confers stability and CNS activity. It is approved as a pharmaceutical in Russia (Семакс) for ischemic stroke, cognitive disorders, and certain ADHD-spectrum presentations in children. Like Selank, it has not been approved in the United States or Western Europe.

Semax was developed beginning in the 1970s by the Institute of Molecular Genetics of the Russian Academy of Sciences with the explicit goal of capturing the neurotrophic effects of ACTH while removing its endocrine effects on the adrenal axis. The result is a peptide with effects on attention, learning, and neuronal protection without producing cortisol elevation. Semax has been in Russian clinical practice for decades and has accumulated substantial published research, primarily in Russian-language journals.

In the US, Semax is available through licensed compounding pharmacies. Intranasal administration is the standard route, providing direct nose-to-brain peptide delivery.

Mechanism of action

Semax acts through multiple integrated CNS pathways:

• BDNF and neurotrophic effects: upregulates brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical regions. This is the leading hypothesized mechanism for cognitive and neuroprotective effects.
• Dopaminergic modulation: increases dopamine availability in attention-relevant brain circuits, contributing to focus and attention enhancement effects.
• Cholinergic effects: influences acetylcholine signaling, supporting cognitive functions including memory and learning.
• Anti-ischemic effects: in animal models of cerebral ischemia, Semax demonstrates neuroprotective effects that have translated to clinical benefit in human stroke recovery.
• HPA axis neutrality: despite being derived from ACTH, the structural modifications eliminate cortisol-stimulating activity. Semax does not affect circulating cortisol or other adrenal steroids.

Research findings

The Russian clinical literature on Semax is substantial:

Acute ischemic stroke: randomized trials have demonstrated improvements in neurological recovery and functional outcomes when Semax is administered in the acute and subacute phases of stroke. This is the indication for which it is most widely used in Russian clinical practice.

Cognitive disorders: studies in cerebrovascular cognitive impairment, post-stroke cognitive decline, and certain dementia presentations support cognitive function improvements.

Attention disorders: Semax has been studied in pediatric ADHD-spectrum presentations in Russia with reported improvements in attention and behavior. The pediatric application has not been replicated in Western settings.

Healthy cognitive enhancement: small studies in healthy adults have explored attention and cognitive performance effects under various conditions including cognitive load and sleep deprivation.

Western RCT replication is limited. Most current clinical use rests on the Russian evidence base, mechanistic understanding, and practitioner experience.

How we use it at The Tide

We prescribe Semax selectively for patients with cognitive concerns who have completed appropriate workup. Typical scenarios:

• Subjective cognitive decline or “brain fog” in adults who have had appropriate medical workup
• Cognitive sequelae of post-viral syndromes (post-COVID, post-EBV) with prominent attention and processing speed concerns
• Recovery from concussion or mild traumatic brain injury, in coordination with neurology
• As an adjunct in patients with attention concerns who have completed appropriate evaluation

Important boundaries: Semax is not a substitute for ADHD evaluation and treatment, dementia workup, or neurological care for cognitive symptoms. We refer patients to neurology, psychiatry, or other specialty care as appropriate. Semax may be a useful adjunct in some scenarios but is not first-line treatment for diagnosed conditions.

Standard dosing: 0.1% or 1.0% intranasal spray (concentration depends on indication), 1–2 sprays per nostril, 2–3 times daily. Cycles are typically 2–4 weeks. Higher concentrations (1.0%) are used for more significant indications; lower (0.1%) for general cognitive support.

What good response looks like: patients typically report subjective improvements in mental clarity, attention, and processing within 1–2 weeks. Effects often emerge gradually rather than acutely. Patients who see no benefit by week 3 are unlikely to benefit from extension.

Side effects and contraindications

Semax is well-tolerated:

• Mild nasal irritation with intranasal use
• Occasional mild head pressure or mild headache
• Rare metallic taste shortly after dosing

Notably, despite its ACTH origin, Semax does not produce cortisol elevation, weight gain, fluid retention, or other adrenocortical side effects. Long-term safety outside Russian clinical practice has not been formally characterized.

Avoided in: pregnancy and breastfeeding, severe psychiatric conditions where psychiatric care is indicated, patients with known peptide allergies, severe seizure disorders (theoretical caution given CNS effects).

What we don’t yet know

Western RCT replication of Russian clinical findings would strengthen the evidence base. Long-term safety with chronic or repeated cyclical use is not well characterized in formal studies. Optimal dosing for various indications is largely informed by Russian clinical practice and may not perfectly translate to Western patient populations and use patterns. Comparative effectiveness vs. conventional cognitive enhancers, attention medications, and behavioral interventions is not well established in head-to-head studies. The fundamental question of whether Semax produces meaningful cognitive enhancement in healthy adults (vs. only in pathological states) is debated and probably overstated in marketing claims. We present Semax honestly: an internationally established cognitive peptide with substantial Russian clinical evidence, used selectively in appropriate patients as part of broader cognitive support strategies.